Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer

Radiotherapy and Oncology

Volumn 106, Issue 1, 2013, Pages 112-117

  Powell, Ceri ^a   Schmidt, Maria ^a   Borri, Marco ^a   Koh, Dow Mu ^a   Partridge, Mike ^a   Riddell, Angela ^a   Cook, Gary ^c   Bhide, Shreerang A ^a,b   Nutting, Christopher M ^a   Harrington, Kevin J ^a,b   Newbold, Katie L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chemotherapy; Head and neck cancer; MRI; PET; Radiotherapy

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOLINIUM;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CERVICAL LYMPHADENOPATHY; CHEMORADIOTHERAPY; CLAUSTROPHOBIA; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; INDUCTION CHEMOTHERAPY; MALE; METABOLISM; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; SUSCEPTIBILITY WEIGHTED IMAGING; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 84874653400     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.09.009     Document Type: Article

References (43)

1. J.P. Pignon, A. le Maitre, and J. Bourhis Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update Int J Radiat Oncol Biol Phys 69 2007 S112 S114
2. E. Cohen, T. Karrison, and M. Kocherginsky DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN) J Clin Oncol 30 2012 (suppl; abstr 5500)
3. J.B. Vermorken, E. Remenar, and C. van Herpen Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 2007 1695 1704 (Pubitemid 350005151)
4. M.R. Posner, D.M. Hershock, and C.R. Blajman Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 2007 1705 1715 (Pubitemid 350005152)
5. S.A. Bhide, M. Ahmed, Y. Barbachano, K. Newbold, K.J. Harrington, and C.M. Nutting Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer Br J Cancer 99 2008 57 62
6. P. Dirix, V. Vandecaveye, and F. De Keyzer Diffusion-weighted MRI for nodal staging of head and neck squamous cell carcinoma: impact on radiotherapy planning Int J Radiat Oncol Biol Phys 76 2010 761 766
7. V. Vandecaveye, P. Dirix, and F. De Keyzer Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma Eur Radiol 20 2010 1703 1714
8. S. Kim, L.A. Loevner, and H. Quon Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging AJNR Am J Neuroradiol 31 2010 262 268
9. P.A. Kyzas, E. Evangelou, D. Denaxa-Kyza, and J.P. Ioannidis 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis J Natl Cancer Inst 100 2008 712 720
10. T. Gupta, S. Jain, and J.P. Agarwal Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo)radiation Radiother Oncol 97 2010 194 199
11. V. Vandecaveye, F. de Keyzer, and V. Vander Poorten Evaluation of the larynx for tumour recurrence by diffusion-weighted MRI after radiotherapy: initial experience in four cases Br J Radiol 79 2006 681 687 (Pubitemid 44283158)
12. V. Vandecaveye, F. De Keyzer, and V. Vander Poorten Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging Radiology 251 2009 134 146
13. P.J. Hoskin, M.I. Saunders, K. Goodchild, M.E. Powell, N.J. Taylor, and H. Baddeley Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer Br J Radiol 72 1999 1093 1098
14. C.A. Uyl-de Groot, A. Senft, R. de Bree, C.R. Leemans, and O.S. Hoekstra Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients J Nucl Med 51 2010 176 182
15. G. Delouya, L. Igidbashian, and A. Houle (1)(8)F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer Radiother Oncol 101 2011 362 368
16. J.D. Murphy, K.M. Chisholm, and M.E. Daly Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity Radiother Oncol 101 2011 356 361
17. E.G. Troost, D.A. Schinagl, J. Bussink, W.J. Oyen, and J.H. Kaanders Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours Radiother Oncol 96 2010 328 334
18. C.M. Nutting, J.P. Morden, and K.J. Harrington Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial Lancet Oncol 12 2011 127 136
19. M.T. Guerrero Urbano, C.H. Clark, and C. Kong Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines Clin Oncol (R Coll Radiol) 19 2007 604 613 (Pubitemid 47308656)
20. M. Ahmed, M. Schmidt, and A. Sohaib The value of magnetic resonance imaging in target volume delineation of base of tongue tumours-a study using flexible surface coils Radiother Oncol 94 2010 161 167
21. D.A. Schinagl, W.V. Vogel, A.L. Hoffmann, J.A. van Dalen, W.J. Oyen, and J.H. Kaanders Comparison of five segmentation tools for 18F-fluoro-deoxy- glucose-positron emission tomography-based target volume definition in head and neck cancer Int J Radiat Oncol Biol Phys 69 2007 1282 1289 (Pubitemid 47625859)
22. J.A. d'Arcy, D.J. Collins, A.R. Padhani, S. Walker-Samuel, J. Suckling, and M.O. Leach Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data Radiographics 26 2006 621 632 (Pubitemid 43515329)
23. O.I. Craciunescu, D.S. Yoo, and E. Cleland Dynamic contrast-enhanced MRI in head and neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters Int J Radiat Oncol Biol Phys 82 3 2012 e345 e350
24. M.R. Orton, J.A. d'Arcy, and S. Walker-Samuel Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI Phys Med Biol 53 2008 1225 1239 (Pubitemid 351594423)
25. C.J. Galban, S.K. Mukherji, and T.L. Chenevert A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy Transl Oncol 2 2009 184 190
26. P. Dirix, V. Vandecaveye, F. De Keyzer, S. Stroobants, R. Hermans, and S. Nuyts Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F- fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI J Nucl Med 50 2009 1020 1027
27. X. Geets, M. Tomsej, and J.A. Lee Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy Radiother Oncol 85 2007 105 115 (Pubitemid 47570061)
28. F. Duprez, W. De Neve, W. De Gersem, M. Coghe, and I. Madani Adaptive dose painting by numbers for head-and-neck cancer Int J Radiat Oncol Biol Phys 80 2011 1045 1055
29. R.N. Moule, I. Kayani, and S.A. Moinuddin The potential advantages of (18)FDG PET/CT-based target volume delineation in radiotherapy planning of head and neck cancer Radiother Oncol 97 2010 189 193
30. S. Kim, L. Loevner, and H. Quon Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck Clin Cancer Res 15 2009 986 994
31. P. Castadot, X. Geets, J.A. Lee, and V. Gregoire Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol 101 2011 343 350
32. A. Edet-Sanson, B. Dubray, and K. Doyeux Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC) Radiother Oncol 102 2012 251 257
33. P. Vera, P. Bohn, and A. Edet-Sanson Simultaneous positron emission tomography (PET) assessment of metabolism with (1)(8)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (1)(8)F-fluoro-thymidine (FLT), and hypoxia with (1)(8)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study Radiother Oncol 98 2011 109 116
34. I. Madani, F. Duprez, and T. Boterberg Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer Radiother Oncol 101 2011 351 355
35. R. Haddad, G. Rabinowits, and R. Tishler The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC) J Clin Oncol 30 2012 (suppl; abstr 5501)
36. J.P. Pignon, A. le Maitre, E. Maillard, and J. Bourhis Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
37. M. Hentschel, S. Appold, and A. Schreiber Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer Eur J Nucl Med Mol Imaging 38 2011 1203 1211
38. M. Yao, R.B. Smith, and M.M. Graham The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment Int J Radiat Oncol Biol Phys 63 2005 991 999 (Pubitemid 41505274)
39. V. Vandecaveye, P. Dirix, and F. De Keyzer Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head and neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 82 3 2012 1098 1107
40. D. Thorwarth, and M. Alber Implementation of hypoxia imaging into treatment planning and delivery Radiother Oncol 97 2010 172 175
41. P. Castaldi, V. Rufini, and F. Bussu Can "early" and "late" 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 103 2012 63 68
42. D.H. Yoon, Y. Cho, and S.Y. Kim Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy Int J Radiat Oncol Biol Phys 81 2011 118 125
43. H. Mehanna, O. Olaleye, and L. Licitra Oropharyngeal cancer-is it time to change management according to human papilloma virus status? Curr Opin Otolaryngol Head Neck Surg 20 2012 120 124